>
Switch to:

ITeos Therapeutics EV-to-EBIT

: -10.09 (As of Today)
View and export this data going back to 2020. Start your Free Trial

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, ITeos Therapeutics's Enterprise Value is $664.87 Mil. ITeos Therapeutics's EBIT for the trailing twelve months (TTM) ended in Jun. 2021 was $-65.87 Mil. Therefore, ITeos Therapeutics's EV-to-EBIT for today is -10.09.

The historical rank and industry rank for ITeos Therapeutics's EV-to-EBIT or its related term are showing as below:

NAS:ITOS' s EV-to-EBIT Range Over the Past 10 Years
Min: -14.49   Med: 0   Max: 0
Current: -10.39

-14.49
0
NAS:ITOS's EV-to-EBIT is ranked lower than
99.99% of the 37 Companies
in the Biotechnology industry.

( Industry Median: 21.16 vs. NAS:ITOS: -10.39 )

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. ITeos Therapeutics's Enterprise Value for the quarter that ended in Jun. 2021 was $601.67 Mil. ITeos Therapeutics's EBIT for the trailing twelve months (TTM) ended in Jun. 2021 was $-65.87 Mil. ITeos Therapeutics's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Jun. 2021 was -10.95%.


ITeos Therapeutics EV-to-EBIT Historical Data

The historical data trend for ITeos Therapeutics's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ITeos Therapeutics Annual Data
Trend Dec18 Dec19 Dec20
EV-to-EBIT
- - -21.60

ITeos Therapeutics Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21
EV-to-EBIT Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - -16.93 -21.60 -18.91 -9.13

Competitive Comparison

For the Biotechnology subindustry, ITeos Therapeutics's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

   

ITeos Therapeutics EV-to-EBIT Distribution

For the Biotechnology industry and Healthcare sector, ITeos Therapeutics's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where ITeos Therapeutics's EV-to-EBIT falls into.



ITeos Therapeutics EV-to-EBIT Calculation

ITeos Therapeutics's EV-to-EBIT for today is calculated as:

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=664.870/-65.866
=-10.09

ITeos Therapeutics's current Enterprise Value is $664.87 Mil.
ITeos Therapeutics's EBIT for the trailing twelve months (TTM) ended in Jun. 2021 adds up the quarterly data reported by the company within the most recent 12 months, which was $-65.87 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


ITeos Therapeutics  (NAS:ITOS) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

ITeos Therapeutics's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Jun. 2021 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Jun. 2021 ) =EBIT / Enterprise Value (Q: Jun. 2021 )
=-65.866/601.671765
=-10.95 %

ITeos Therapeutics's Enterprise Value for the quarter that ended in Jun. 2021 was $601.67 Mil.
ITeos Therapeutics's EBIT for the trailing twelve months (TTM) ended in Jun. 2021 adds up the quarterly data reported by the company within the most recent 12 months, which was $-65.87 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


ITeos Therapeutics EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of ITeos Therapeutics's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


ITeos Therapeutics Business Description

ITeos Therapeutics logo
Industry
Healthcare » Biotechnology NAICS : 541714 SIC : 2833
Comparable Companies
Traded in Other Exchanges
N/A
Address
139 Main Street, Cambridge, MA, USA, 02142
ITeos Therapeutics Inc is a biopharmaceutical company engaged in the discovery and development of immuno-oncology therapeutics for patients. Its product candidates include EOS-850 which is an Adenosine A2A receptor-specific antagonist and EOS-448 which is an ADCC-enabled, anti-TIGIT immune checkpoint blocking antibody.
Executives
Evnin Luke 10 percent owner THE JOHN HANCOCK TOWER 200 CLARENDON STREET, 54TH STREET BOSTON MA 02116
Mpm Bioventures 2018 Llc 10 percent owner 450 KENDALL STREET CAMBRIDGE MA 02142
Mpm Bioventures 2018 Gp Llc 10 percent owner 450 KENDALL STREET CAMBRIDGE MA 02142
Mpm Asset Management Investors Bv2018 Llc 10 percent owner 450 KENDALL STREET CAMBRIDGE MA 02142
Mpm Bioventures 2018, L.p. 10 percent owner 450 KENDALL STREET CAMBRIDGE MA 02142
Mpm Bioventures 2018 (b), L.p. 10 percent owner 450 KENDALL STREET CAMBRIDGE MA 02142
Mpm Bioventures 2014 Gp Llc 10 percent owner 450 KENDALL STREET CAMBRIDGE MA 02142
Mpm Bioventures 2014 Llc 10 percent owner 450 KENDALL STREET CAMBRIDGE MA 02142
Mpm Asset Management Investors Bv2014 Llc 10 percent owner C/O MPM ASSET MANAGEMENT LLC 450 KENDALL STREET CAMBRIDGE MA 02142
Mpm Bioventures 2014 (b), L.p. 10 percent owner C/O MPM ASSET MANAGEMENT LLC 450 KENDALL STREET CAMBRIDGE MA 02124
Mpm Bioventures 2014, L.p. 10 percent owner C/O MPM ASSET MANAGEMENT LLC 450 KENDALL STREET CAMBRIDGE MA 02142
Oncology Impact Fund (cayman) Management L.p. other: X* 450 KENDALL STREET CAMBRIDGE MA 02142
Mpm Oncology Impact Management Gp Llc other: X* 450 KENDALL STREET CAMBRIDGE MA 02142
Ubs Oncology Impact Fund L.p. other: X* 450 KENDALL STREET CAMBRIDGE MA 02142
Davis Aaron I. director, 10 percent owner 11682 EL CAMINO REAL, SUITE 320 SAN DIEGO CA 92130

ITeos Therapeutics Headlines

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)